Table 2.

The main randomized trials in gastric cancer that evaluate the preoperative therapy

Trial	Year	Randomization scheme	OS	DFS, PFS	Limits
MAGIC[25]	2006	S-alone vs CT + S + CT	5-yr 23% vs 36% (P = 0.009)	3-yr 26% vs 38% (P < 0.001)	Low adherence to post-operative CT, inclusion of gastroesophageal junction or lower esophagus cancer
FNCLCC/ FFCD[26]	2011	S-alone vs CT + S + CT	5-yr 24% vs 38% (P = 0.02)	5-yr 19% vs 34% (P = 0.003)	Inclusion of gastroesophageal junction or lower esophagus cancer, small series
MAGIC-B[28]	2017	CT/Beva + S + CT/ Beva vs CT + S + CT	3-yr 48.1% vs 50.3% (P = 0.36)	NR	Inclusion of gastroesophageal junction or lower esophagus cancer
POET trial[29]	2009	CT + S vs CT + CRT + S	3-yr 27.7% vs 47.4% (P = NS)	NR	Gastroesophageal junction tumors, closed earlier

OS: Overall survival; DFS: Disease-free survival; PFS: Progression-free survival; RT: Radiotherapy; S: Surgery; CT: Chemotherapy; CRT: Chemoradiation; NR: Not reported; NS: Not significant; Beva: Bevacizumab.